Sidonia Fagarasan, MD, PhD

RIKEN Yokohama Campus
Yokohama Japan
Biographical Sketch: Sidonia Fagarasan completed training in clinical medicine at Iuliu Hatieganu University of Medicine and Pharmacy in 1990. She did residency and speciality in the Clinical Laboratory for Microbiology, Biochemistry and Hematology at the University of Medicine and Pharmacy, Cluj-Napoca, and was appointed to Assistant Professor in 1995. It was during this clinical period in Romania that Dr Fagarasan developed a fascination into the mechanisms governing intestinal immune homeostasis. In 1998, Dr Fagarasan was invited to Japan as a Mombusho Visiting Researcher and earned PhD from Kyoto University Faculty of Medicine in 2000. In Kyoto she contributed to the discovery of Activated Induced Deaminase (AID) with Tasuku Honjo and colleagues. She subsequently demonstrated the critical role of AID in gut homeostasis.Since 2002, Dr Fagarasan has been team leader of the Laboratory for Mucosal Immunity at the Research Centre for Allergy and Immunology (RCAI), RIKEN Yokohama, Japan. Dr. Fagarasan’s research primarily aims to elucidate mechanistic regulation and function of the mucosal antibody IgA in the gut.

Any personal financial relationships? No

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 06/25/2015 by Sidonia Fagarsan

Papers:
How Adaptive Immune System Contributes to Maintenance of Diversified and Balanced Microbiota in the Gut

	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".